Minerva Neurosciences (NASDAQ:NERV) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a report published on Sunday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright dropped their price objective on shares of Minerva Neurosciences from $7.00 to $5.00 and set a neutral rating on the stock in a report on Wednesday, August 7th.

Minerva Neurosciences Stock Down 2.1 %

Shares of NASDAQ NERV opened at $2.85 on Friday. The company’s fifty day moving average is $2.90 and its 200-day moving average is $2.80. The stock has a market cap of $19.93 million, a price-to-earnings ratio of -0.64 and a beta of 0.14. Minerva Neurosciences has a twelve month low of $2.26 and a twelve month high of $13.49.

Minerva Neurosciences (NASDAQ:NERV) last issued its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.12). On average, research analysts anticipate that Minerva Neurosciences will post -2.26 EPS for the current fiscal year.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.